เว็บไซต์คืออะไร?

http://www.GreenCultureLabs-Thailand.com/

Green Culture Labs co., Ltd, Amphoe Wat Bot (2025)

27/11/2025

Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis: Cannabis Sativa’s Structures

A scientific study on Cannabinoids, Phenolics, Terpenes, and Alkaloids of Cannabis provides a detailed look into the complex chemical composition of Cannabis sativa.

• This study is crucial for understanding the plant's medicinal potential and its broad phytochemical diversity.

• The Chemical Makeup of Cannabis Categories and Key Compounds
A recent scientific review analyzed the entire chemical profile of Cannabis sativa.

✔️ Researchers confirmed the presence of over 500 plus total compounds which are classified into two major categories.

I. Cannabinoids (Total: 125 Identified Compounds)
These are the primary compounds unique to the plant, determining its psychoactive and therapeutic properties.

They are typically found in acidic forms (ending in -A) before being converted into neutral forms.

• Delta-9-THC Type
• Delta-9-Tetrahydrocannabinol (THC)
• THC Acid A (THCA-A)

• Cannabidiol (CBD) Type
• Cannabidiol (CBD)
• Cannabidiolic Acid (CBDA)

• Cannabigerol (CBG) Type
• Cannabigerol (CBG)
• Cannabigerolic Acid (CBGA)

• Cannabinol (CBN) Type
• Cannabinol (CBN)
• Cannabinolic Acid (CBNA)

✔️ Other Key Sub-Classes

• Cannabichromene (CBC)
• Cannabicyclol (CBL)
• Cannabitriol (CBT)
• Cannabinodiol (CBND)

II. Non-Cannabinoid Constituents
These compounds are responsible for the plant’s distinct flavor aroma and contribute to its overall effects.

• Terpenes and Terpenoids (Over 120 Types)

• Examples Myrcene Limonene Linalool Beta-Caryophyllene

✔️ Flavonoids (Over 26 Types)

• Examples Cannflavin A Cannflavin B Quercetin

• Non-Cannabinoid Phenols

• Includes Phenolic Acids and Stilbenoid Derivatives

✔️ Alkaloids and Others
Includes nitrogen-containing Alkaloids Sterols and Fatty Acids

✔️ Total Chemical Complexity

• Cannabis sativa is one of the world's oldest medicinal plants containing a sophisticated mixture of secondary metabolites.

• The plant is reported to contain over 500 chemical compounds in total.

✔️ Cannabinoids The Signature Compounds

• The review confirms 125 different cannabinoids have been isolated or identified from the plant.

• Cannabinoids are a unique class of \text{C}_{21} terpeno-phenolic compounds specific to Cannabis.

• The study examines the chemistry of several major groups including Cannabicyclol CBL Cannabichromene CBC and Cannabinol CBN.

✔️ Non-Cannabinoid Constituents

• The plant’s overall effect is shaped by a variety of non-cannabinoid compounds.

• Key non-cannabinoid categories discussed include Terpenes Flavonoids Alkaloids and other Phenolics.

Understanding the specific structures and characteristics of these 500+ compounds is essential for modern pharmacological research and product standardization.

Source to Study; Read Here ⬇️

https://www.mdpi.com/1420-3049/26/9/2774

25/11/2025

Cannabis sativa L. Leaves as a Source of Bioactive Compounds

Comprehensive Chemical Characterization of Non-Psychotropic H**p Varieties.

This study provides a detailed chemical analysis of the leaves from four distinct non-psychotropic Cannabis sativa (h**p) chemotypes.

The research aims to establish a comprehensive profile of important non-cannabinoid compounds.

Study Focus

• The research characterized the qualitative and quantitative composition of four major compound classes

• Polyphenols
• Cannabinoids
• Policosanols
• Terpenes

H**p Varieties Analyzed

✔️ CBD-type
✔️ CBG-type
✔️ CBC-type
✔️ Cannabinoid-free type

Key Results on Polyphenols

✔️ Advanced analytical methods were used to identify and quantify key compounds including Cannflavin-A CFL-A and Cannflavin-B CFL-B

✔️ Cannflavin-A was consistently found at higher quantitative levels than Cannflavin-B across the samples analyzed

✔️ Demethoxy Cannflavins were identified as significantly abundant in one specific variety.

This comprehensive chemical profile is vital for understanding the full therapeutic and industrial potential of h**p beyond the primary cannabinoids.

Takeaway

Non-cannabinoid compounds in h**p leaves, such as polyphenols, terpenes, alkaloids, and policosanols — offer anti-inflammatory, antioxidant, neuroprotective, and cosmetic benefits, making them valuable for pharmaceutical and industrial applications.

Waste to Wealth and Health

✔️ Previously: Another Study
25 compounds had never before been reported in cannabis.
September 10, 2025

• Scientists at Stellenbosch University, identified 79 phenolic compounds in certain commercial cannabis strains.

• 79 phenolic compounds were identified across the three strains.

• 25 compounds had never before been reported in cannabis.

• 16 compounds were tentatively identified as flavoalkaloids-a rare hybrid class combining flavonoid and alkaloid structures.

Published Date:
November 10, 2025
Source(s) Here with detailed list of compounds. ⬇️

Exploring the Chemical Space around Cannabis sativa L. Leaves as a Source of Bioactive Compounds of Pharmaceutical Interest.

Date: November 10, 2025

https://assets-eu.researchsquare.com/files/rs-7941302/v1/646fb87d-b563-4710-826d-ae5998460cbb.pdf?c=1762877425

September 10, 2025

Researchers have discovered rare compounds called flavoalkaloids in cannabis leaves, which have potential pharmaceutical value.

These flavoalkaloids were primarily found in the leaves of one specific strain. (Specific strain was not publicly made available)

https://www.sciencedaily.com/releases/2025/09/250910000258.htm

20/11/2025

Synergistic Potential of Cannabis and Propolis for Antibacterial and Anti-Inflammatory Applications: An In Vitro Study

Combined effects of Cannabis sativa extracts and propolis (Bee-made resin) against bacterial pathogens and inflammatory responses.

The findings support the development of safe, plant-based therapeutics for respiratory and throat-related conditions.

✔️ Antibacterial Activity

• Cannabis sativa extract and propolis both inhibited Streptococcus pyogenes, Staphylococcus aureus, and Pseudomonas aeruginosa

• The combination showed additive antibacterial effects, especially against Gram-positive bacteria

• Cannabidiol (CBD) was identified as the primary antibacterial compound in cannabis extract

✔️ Anti-Inflammatory Effects

• The combination significantly reduced nitric oxide (NO) production in LPS-stimulated macrophages

• Suppressed key inflammatory cytokines including IL-6, IL-8, and TNF-alpha

• Optimal anti-inflammatory effect observed at 625 µg/mL propolis and 0.125 µg/mL CBD

✔️ Safety and Therapeutic Implications

• No cytotoxicity observed in RAW264.7 macrophage cells at tested concentrations

• Results support the potential for safe oral or topical formulations targeting inflammation and infection

• Further studies recommended to explore hepatotoxicity and confirm mechanisms in vivo

This research reinforces the value of integrating cannabinoid science with traditional bioactive compounds like propolis.

It opens new pathways for evidence-based botanical therapeutics in regulated healthcare settings.

A recent peer-reviewed study published in the International Journal of Molecular Sciences.
(Study out of Thailand 🇹🇭)

Other studies Cannabis shows promising antiviral potential, with cannabinoids like CBD and THC demonstrating activity against viruses such as SARS-CoV-2, HIV, hepatitis C, and herpes simplex in laboratory studies

Published:
November 19, 2025
Source(s) Here ⬇️

Enhanced Antibacterial and Anti-Inflammatory Activities of the Combination of Cannabis sativa and Propolis Extracts: An In Vitro Study.

November 19, 2025

https://www.mdpi.com/1422-0067/26/22/11181

Anti-Inflammatory and Antiviral Effects of Cannabinoids in Inhibiting and Preventing SARS-CoV-2 Infection.

April 10, 2022

https://www.mdpi.com/1422-0067/23/8/4170

08/11/2025

“Anyone who stops learning is old, whether at twenty or eighty. Anyone who keeps learning stays young.”

― Henry Ford

06/11/2025

Global Medical Cannabis Market Boom: Why Doctors and Patients Are Embracing Green Medicine

✔️ Overview

The global medical cannabis market is accelerating as doctors and patients recognize cannabis as a legitimate therapeutic option.

Once viewed as alternative, it is now entering mainstream medicine in North America, Europe, and Asia-Pacific, where Thailand and Australia are emerging leaders.

Thailand potential Supply Disruptors with GACP - GMP Grade - Lower Cost of Production while energy prices remain high elsewhere 💲

✔️ Key Growth Drivers

• Legalization and Policy Support – Expanding laws enable regulated cultivation, research, and patient access.

• Chronic Disease Demand – Pain, cancer, and neurological disorders drive the shift toward plant-based treatments.

• Research and Validation – Clinical studies continue to confirm cannabinoid efficacy for pain, anxiety, and nausea.

• Advanced Formulations – New extraction and dosing technologies deliver consistent quality and efficacy.

• Changing Perception – Education and safety data are reducing stigma among healthcare providers and patients.

✔️ Market Segments

• Products – Oils and extracts dominate, followed by dried flowers, capsules, and edibles.

• Applications – Chronic pain leads, followed by oncology, neurology, and mental health.

• Distribution – Hospitals, clinics, pharmacies, and licensed online sales drive access.

• Regions – North America leads, Europe expands rapidly, Asia-Pacific shows rising potential.

✔️ Competitive Landscape

Major players — Canopy Growth, Tilray, Aurora, Cronos, and GW Pharmaceuticals — lead global supply chains.

Partnerships and research alliances are shaping pharmaceutical-grade, standardized cannabis medicines.

✔️ Challenges

• Fragmented regulations and limited clinical data slow adoption.

• High GMP production costs and infrastructure gaps raise prices.

• Social stigma and supply chain limitations restrict access.

✔️ Outlook

Medical cannabis is set for sustained global growth.

AI, precision agriculture, and personalized cannabinoid therapies will enhance quality, safety, and patient outcomes.

Future success depends on rigorous GMP standards, scientific validation, and continued policy reform.

Article Date:
November 6, 2025
Source to article Read Here ⬇️

The Medical Cannabis Market Boom Why Doctors and Patients Are Embracing Green Medicine.

November 6, 2025

https://paidforarticles.in/the-medical-cannabis-market-boom-why-doctors-and-patients-are-embracing-green-medicine-895371

03/11/2025

Multi-Therapeutic Potential of Mitragyna speciosa (Kratom) Alkaloids

2025 Review Summary
(Begum et al., 2025 — ScienceDirect, DOI S2307410825000252)

✔️ Overview

• 2025 review compiles 150 + studies on chemistry, pharmacology, extraction, and safety of Mitragyna speciosa.

• Focuses on mitragynine and 7-hydroxymitragynine with attention to minor alkaloids and combined bioactivity.

• Purpose — clarify therapeutic promise and research gaps for clinical, regulatory, and industrial advancement.

✔️ Phytochemistry and Extraction

• Mitragynine makes up 40–66% of total alkaloids; 7-hydroxymitragynine occurs in trace amounts but has far greater μ-opioid potency.

• Over 50 additional alkaloids identified (speciociliatine, paynantheine, mitraphylline, corynantheidine).

• Alkaloid profiles shift with leaf age, origin, drying, solvent, pH, and temperature.

• Authors call for green, scalable extraction methods adaptable to GMP and pharma production.

✔️ Pharmacological Findings

• Mitragynine acts as partial μ-opioid agonist with adrenergic and serotonergic modulation — stimulant at low dose, analgesic at higher dose.

• Recent Preclinical studies show’s Mitragynine did not have respiratory suppression and may increase breathing under certain circumstances.

• 7-Hydroxymitragynine is a potent μ-agonist responsible for most analgesic strength in vivo.

• Documented activities include analgesic, anti-inflammatory, antioxidant, antidepressant, neuroprotective, anti-addictive, and antitumour effects.

• Human data remain limited; most evidence is pre-clinical.

• Both alkaloids show G-protein-biased agonism with reduced β-arrestin recruitment, suggesting lower respiratory risk.

✔️ Safety and Toxicology

• Adverse effects include dependence, hepatic and cardiovascular stress.

• Toxicity often linked to poly-alkaloid mixtures or adulterants rather than pure compounds.

• Oxidative conversion of mitragynine → 7-OH demands stability and impurity control. (RnD requires maximum purity for control effects)

• Comprehensive toxicology and dose-controlled clinical trials are required.

✔️ Analytical and Quality Control

• Lack of standardised quantification hampers comparability.

• HPLC-DAD and LC-MS/MS recommended with full ICH Q2(R1) validation.

• Fingerprinting via LC-HRMS supports authenticity and batch consistency.

• Stability testing under ICH Q1A(R2) should track degradation and oxidation.

• Reference materials for major and minor alkaloids are essential for GMP manufacture.

✔️ Research Gaps and Future Work

• Profile roots, stems, flowers, under-studied plant parts.

• Link chemotype to bioactivity and safety via integrated metabolomics and toxicology.

• Design validated human dose-response trials to define therapeutic margin and dependence risk.

• Adopt computational modeling and in-silico ADMET for new analogue screening.

• Develop international reference libraries and SOP alignment for regulators.

✔️ Key Takeaway

Mitragyna speciosa shows diverse alkaloids with promising multi-therapeutic effects.

Translating this potential demands GMP-standardised chemistry, validated analytics, and rigorous clinical evidence before mainstream pharmaceutical use.

Kratom-derived Alkaloids Redefining Pain Relief Science: Recent Research

• A new study highlights how two key kratom compounds, Mitragynine and Corynoxeine, may work together to achieve powerful, self-limiting pain relief through multiple biological systems.

• Mitragynine, the dominant indole alkaloid, acts as a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, producing analgesia without activating the β-arrestin-2 pathway responsible for respiratory depression, constipation, and rapid tolerance in traditional opioids.

• Recent findings confirm mitragynine does not suppress breathing, in fact, it may slightly increase respiratory drive (under certain conditions), a crucial safety distinction from morphine or fentanyl.

Source to 2025 Study Here ⬇️

A review on multi-therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine: Experimental evidence and future perspectives

https://www.sciencedirect.com/science/article/pii/S2307410825000252

Kratom’s alkaloids act on multiple biological systems to produce comprehensive analgesia and neuroprotection.

How Kratom Targets Five Physiological Pathways of Pain

1. Central μ-opioid receptor G-protein signaling → potent yet respiration-sparing analgesia

2. Descending serotonergic and adrenergic modulation → spinal inhibition of pain signals

3. Peripheral anti-inflammatory suppression (NF-κB / COX-2) → reduced cytokines and prostaglandins

4. TRPV1 nociceptor desensitization → decreased neuropathic pain and thermal sensitivity

5. Endocannabinoid cross-talk → sustained anandamide tone and prolonged relief

6. Nrf2 antioxidant activation → long-term neuroprotective and tissue-healing effects

——————————————————-

Source to Study Below ⬇️

Exploring the Therapeutic Potential of Mitragynine and Corynoxeine: Kratom-Derived Indole and Oxindole Alkaloids for Pain Management.

Published: 6 February 2025

https://www.mdpi.com/1424-8247/18/2/222

30/10/2025

Medicinal Plants Targeting the Five Primary Physiological Pathways of Pain

Pain affects how we think feel and connect with others making it one of the most disruptive health challenges worldwide.

Modern research continues to highlight how natural plant compounds can effectively target pain pathways while minimizing the side effects often seen with synthetic drugs

✔️ Key Findings

• Scientists have identified multiple medicinal plants that act on the body’s natural pain control systems including the opioid serotonergic and endocannabinoid networks

• These botanicals contain bioactive compounds that interact with receptors in the brain and nerves helping to reduce inflammation calm pain signaling and restore emotional balance

• The 2025 Phytotherapy Research review emphasizes that multimodal botanical agents can deliver clinically meaningful pain relief through mechanisms overlapping with pharmaceutical opioids antidepressants and anti inflammatory drugs but with improved safety and tolerance profiles

✔️ Leading Medicinal Plants and Their Mechanisms

• Kratom (Mitragyna speciosa)
Activates μ opioid receptors and α2 adrenergic pathways producing analgesia comparable to morphine but with a ceiling/adverse effects such as respiratory depression, constipation, and physical dependency.

• Psilocybin (Psilocybe spp.)
Targets 5 HT2A serotonergic receptors promoting neuroplasticity and emotional reframing of chronic pain while modulating perception and mood

• Cannabis (Cannabis sativa)
Stimulates CB1 and CB2 receptors of the endocannabinoid system reducing neuropathic and inflammatory pain while improving stress and sleep regulation

• Turmeric (Curcuma longa)
Curcumin inhibits NF κB transcription factor and desensitizes TRPV1 pain receptors leading to potent anti inflammatory antioxidant and neuroprotective effects

• Capsaicin (Capsicum annuum) Repeatedly activates and then desensitizes TRPV1 receptors decreasing localized nerve pain and hypersensitivity

• White Willow (Salix alba)
Contains salicin which converts into salicylic acid to inhibit COX enzymes and block prostaglandin synthesis reducing inflammation and swelling

✔️ Why It Matters

• These plant compounds act on the same biological systems as many prescription drugs but with lower toxicity and reduced potential for dependence

• Their ability to engage multiple receptor systems simultaneously makes them ideal for complex pain syndromes such as neuropathic fibromyalgic and inflammatory pain

• Combining traditional botanical wisdom with modern pharmacology can guide the creation of standardized botanical medicines offering safer long term solutions

✔️ Takeaway

Nature remains one of the richest sources of safe effective and affordable pain treatments. Understanding how these plants interact with human receptor networks allows the development of next generation analgesics that unite traditional knowledge and scientific precision

October 22, 2025

Source to Study Here ⬇️

Plant-Derived Compounds: A Potential Treasure for Development of Analgesic and Antinociceptive Therapeutics.

October 22, 2025

https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.70113

25/10/2025

Global wastewater study finds Kratom Alkaloid Mitragynine to be the world’s most detected new psychoactive substance (NPS).

• An international research team analyzed wastewater from 52 treatment plants across 20 countries covering more than 20 million people to identify new psychoactive substances (NPS)

• Advanced LC-MS/MS and solid-phase extraction methods detected 21 new psychoactive compounds including plant alkaloids, synthetic cathinones, benzodiazepines, opioids, and dissociatives

✔️ Mitragynine, the primary alkaloid from Mitragyna speciosa (kratom), was the most frequently detected compound appearing at 38 of 55 global sites and showing the highest population-normalized mass loads

• This marks the first time a natural plant alkaloid surpassed synthetic designer drugs such as 3-MMC and eutylone in global surveillance studies

✔️ 3-MMC and eutylone ranked next followed by synthetic opioids and benzodiazepines including protonitazene and bromazolam

✔️ Synthetic opioid protonitazene was detected in the United States confirming the international spread of potent nitazene analogues similar in effect to fentanyl.

• 2020 NIH stats with 20 Million active Kratom users in America alone, it’s now 2025.

• Cannabis, Co***ne and traditional opioids like morphine were not directly measured in this study but are monitored through separate international wastewater programs

✔️ The research validated long-term sample stability for up to four months at −20 °C enabling consistent intercontinental testing and comparison

• Analysis of European data showed a clear decline in 3-MMC following new legislation introduced between 2022 and 2023 demonstrating how wastewater data can track policy impact in real time

✔️ List of detected compounds from highest to lowest prevalence:

•Mitragynine
•3-Methylmethcathinone (3-MMC)
•Eutylone
•Mephedrone
•N,N-Dimethylpentylone
•Pentylone
•3,4-Methylenedioxy-PV8
•Bromazolam
•Desalkylflurazepam
•Flubrotizolam
•Flubromazolam
•Etizolam
•2F-DCK (2-Fluorodeschloroketamine)
•2-Oxo-PCE
•Hydroxetamine
•Protonitazene
•3-Chlorophenmetrazine
•Phenibut
•Alpha-D2PV
•Butylone and Dibutylone

✔️ Key insight

Mitragynine’s detection in multiple continents highlights kratom’s growing global use as a natural psychoactive substance and its emergence as a new class within wastewater epidemiology

• Wastewater analysis continues to prove its value as a global early-warning system connecting laboratory science, drug-policy evaluation, and public-health monitoring

✔️ Takeaway

• Mitragynine has overtaken synthetic stimulants as the most prevalent psychoactive compound detected in wastewater worldwide. Its rise shows the expanding role of natural alkaloids in modern psychoactive markets and the need for ongoing regulatory, clinical, and quality-control research.

New Psychoactive Substance (NPS) in global wastewater indicates widespread Kratom Consumption across multiple continents. It shows Kratom’s transition from regional Southeast Asian use to Global Exposure.

Published Date:
October 21, 2025

Source to Study Here:

https://www.sciencedirect.com/science/article/pii/S0043135425017506

24/10/2025

Spain Approves Hospital-Only Medicinal Cannabis Law

Spain has officially approved a new regulatory framework for medicinal cannabis, limiting its use to hospital settings under strict specialist oversight.

• Only hospital pharmacies can formulate and dispense medical cannabis

• Only specialist doctors are allowed to prescribe cannabis, not general practitioners

• AEMPS (Spanish medicines agency) will define each product’s approved indication, dosage and formulation through official monographs

• Cannabis formulas must be standardised preparations with defined THC and CBD content

• Preparations over 0.2% THC face tighter restrictions and controlled substance tracking

• All supply chain actors must maintain full documentation, GMP-style traceability and quality control

• Manufacturers must apply to AEMPS and prove their formulations meet standardisation and safety requirements

• Likely starting indications include MS-related spasticity, refractory epilepsy, chemotherapy-induced nausea, and chronic pain

• Over-the-counter sales remain prohibited under this law, which applies only to hospital use

• Future expansion of indications is possible based on scientific evidence and new monographs

✔️ This model emphasizes safety, medical oversight and pharmaceutical-grade quality control, setting a high regulatory bar for cannabis as a true medicine.

Cannabis flowers (raw plant material for smoking or vaporization) are not allowed.

Royal Decree (Real Decreto) approved by the Spanish government on October 7, 2025

Full Article Here ⬇️

——————————————
https://elpais.com/sociedad/2025-10-07/el-gobierno-aprueba-el-uso-del-cannabis-medicinal-solo-en-hospitales-y-recetado-por-especialistas.html

22/10/2025

Carvone (Spices) Conversion into CBD Cannabidiol enantiomers: as Novel Anticonvulsants

✔️ Carvone is a natural monoterpene found in Caraway, Dill, and Spearmint, used as a chiral precursor in synthesizing menthol, antiviral agents, and other pharmaceutical intermediates.

• Researchers have successfully transformed carvone (derived from caraway seeds) natural monoterpene into pure CBD-like compounds using a five-step synthetic process

• This approach replaces the cannabis plant as the source of cannabidiol by starting from a non-cannabis botanical compound and reconstructing its active molecular framework through controlled synthesis

• The process ensures total control over stereochemistry, purity, and potency while eliminating THC contamination and agricultural variability

• Among all analogues tested, the long-chain CBD variant demonstrated strong anticonvulsant effects in animal seizure models with no sedation or motor impairment

• Development of these carvone-based CBD molecules could provide safer, more stable pharmaceutical alternatives for treating resistant epilepsies and neurological disorders.

Carvone-based CBD represents a strategic opportunity for nations to pursue cannabinoid-inspired therapies without legal or agricultural dependence on cannabis or h**p.

✔️ Feasibility Implications and Implementation

• Carvone-derived synthetic CBD is more feasible and regulator-friendly (non-narcotic cannabinoids), compared to cultivation of Cannabis Sativa L.(A prohibited Plant in many countries)

• The Carvone-derived CBD analogue may serve as a potential chemical intermediate for synthesizing other cannabinoids through further synthetic modification, although no research has yet confirmed or demonstrated this pathway.

Published:
September 24, 2025

Source Here ⬇️

Carvone derived cannabidiol enantiomers as novel anticonvulsants.

https://www.nature.com/articles/s41386-025-02220-1

22/10/2025

Malaysia opens pathway for cannabis-based medical products

• The Ministry of Health Malaysia has officially opened the door for companies and researchers to register cannabis-based products for medical use

• Applicants must provide sufficient scientific evidence proving the safety, quality, and efficacy of cannabis-derived compounds before approval

• Cannabis remains regulated under the Dangerous Drugs Act 1952 and the Poisons Act 1952 meaning strict compliance with existing drug and poison control laws is required

• The decision does not legalize recreational use but creates a regulated route for scientifically validated cannabis formulations to enter the healthcare system

• The announcement came through a written parliamentary reply by Dr Kelvin Yii Lee Wuen who asked if medical ma*****na would be allowed in Malaysia

• The Ministry confirmed that all activities related to importation, sale, possession, or supply of cannabis remain prohibited unless authorized for approved medical or research purposes.

• This marks a major policy shift toward evidence-based evaluation rather than blanket prohibition of cannabis in Malaysia’s healthcare

• For botanical extract researchers and manufacturers this creates opportunity to develop GMP-standard cannabis extracts backed by analytical data from HPLC, GC-MS, and NMR testing

• Thailand’s current medical cannabis GMP producers may have opportunities to assist our neighboring country starting their own medicinal cultivation and processing.

• Scientific and regulatory readiness will determine which companies can move fastest to meet Malaysia’s new medical cannabis standards

• The country joins a growing list of Asian nations cautiously adopting medical cannabis frameworks anchored in pharmaceutical evidence and strict quality control

March 2025

As of 2025, Malaysia maintains strict drug laws under the Dangerous Drugs Act 1952, imposing death or life imprisonment for trafficking, severe penalties for possession, and tight controls on medical cannabis research and licensing.

Full Article Here ⬇️

Health Ministry opens door for Cannabis-based products in medical treatment: Kuala Lumpur, Malaysia 🇲🇾

https://www.thestar.com.my/news/nation/2025/03/04/health-ministry-opens-door-for-cannabis-based-products-in-medical-treatment?utm_source=chatgpt.com

16/10/2025

New Cannabis Analog Outperforms Morphine: Pre-Clinical

Previous Post on VER-01 a full spectrum cannabis extract showing efficacy and safety profile superior to traditional opiates. (3rd Phase Clinical Trial)

Today’s Post MIRA-55 shows morphine-level pain relief + anti-inflammation effect in preclinical tests potential non-opioid analgesic breakthrough (Pre-Clinical)

✔️ Key Findings from the Study

• In a formalin inflammatory pain model, MIRA-55 reduced pain sensitivity ~3×, returning pain thresholds close to baseline

• Analgesic efficacy matched that of morphine in the same model

• No sedation or swelling was observed with MIRA-55 treatment

• The U.S. DEA determined MIRA-55 is not a controlled substance, removing a major regulatory barrier

• Earlier studies also showed MIRA-55 blocked thermal and mechanical hyperalgesia without increasing inflammation, while low-dose THC exacerbated inflammation in similar tests

✔️ Mechanistic Profile & Design

• MIRA-55 is a synthetic analog engineered to selectively activate CB2 receptors (pain + anti-inflammatory) with minimal CB1 activity (psychoactive)

• It offers a favorable pharmacological balance: higher efficacy at both CB1 and CB2 compared to THC, with sustained agonist activity across increasing doses

✔️ Implications & Outlook

• If translation to humans holds, MIRA-55 could become a much safer alternative to opioids for chronic inflammatory pain

• The non-controlled status accelerates the path to clinical trials and reduces regulatory complexity

• Next steps include filing an IND and initiating human safety / efficacy trials

✔️ Nearly 60% of modern medicines are derived or inspired by nature, with plants, fungi, and marine organisms providing the molecular blueprints for today’s most effective drugs.

Strict scheduling 1 of natural Cannabis blocks and create prohibiting regulation for RnD, pushing pharma to design synthetic analogs instead of developing real plant-based medicines.

✔️ Despite discovering the endocannabinoid system over 30 years ago, a master regulator of pain, mood, and immunity, most universities still offer no formal courses on it, while pharmaceutical companies quietly advance synthetic cannabinoid analogs to exploit its untapped therapeutic potential.

October 16, 2025

Mira Pharmaceuticals press release on preclinical data for MIRA-55 and Article Here ⬇️

MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Ma*****na Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks.

https://mirapharmaceuticals.com/mira-reports-potent-inflammatory-pain-relief-from-non-psychoactive-ma*****na-analog-mira-55-in-animal-model-matching-morphine-without-opioid-risks/

Green Culture Labs co., Ltd

27/11/2025

25/11/2025

20/11/2025

08/11/2025

06/11/2025

03/11/2025

30/10/2025

25/10/2025

24/10/2025

22/10/2025

22/10/2025

16/10/2025

ที่อยู่

เว็บไซต์

แจ้งเตือน

ทางลัด

แชร์

ประเภท